Gary Jacob, Ph.D.

Company: OKYO Pharma Ltd.

Job title: Chief Executive Officer

Seminars:

Clinical Development of Urcosimod, a Drug Candidate Targeting CMKLR1 (ChemR23), to Treat Eye Disease & Neuropathic Corneal Pain 3:30 pm

Spotlighting results from randomized Phase 2b clinical trials of the lipidated peptide urcosimod to treat dry eye disease (DED) and neuropathic corneal disease (NCP) Covering in vitro and animal model data on urcosimod, an agonist of the ChemR23 receptor, that led to the decision to develop urcosimod to treat NCP and DED Providing advice for…Read more

day: Conference Day Two